DEEP PHARMA INTELLIGENCE

About Deep Pharma Intelligence

Deep Pharma Intelligence (DPI) is a leading UK-based strategic and investment intelligence agency focused on the emerging markets in the Pharmaceutical, Biotech, and Healthcare Tech industries.

Deep Pharma Intelligence is a joint venture created by **Deep Knowledge Analytics Pharma Division** and **BPT Analytics (BiopharmaTrend)** -- two highly specialized think tanks in the area of biotech innovation profiling, business intelligence, and biotech investment advisory. The company is dedicated to producing powerful data mining and visualization systems, interactive analytics tools, and industry reports offering deep technical insights, business intelligence, and strategic guidance in the high growth and significant opportunity areas of the pharmaceutical industry, including artificial intelligence (AI) in drug discovery, emerging therapeutic targets and drug modalities, new therapies and technologies, promising startups, and more.

Our Value Proposition:

Open Access and Proprietary Reports

Deep Pharma Intelligence is producing regular open access reports covering emerging bio-pharmaceutical markets -- technologies, innovations, companies, and trends.

Our clients and partners can enjoy access to proprietary reports, featuring additional in-depth research conducted by our team on regular basis.

IT-Platform and Big Data Analytics Dashboard

Our company is building a sophisticated cloud-based engine for advanced market and business intelligence in the pharmaceutical and healthcare industries. It includes data mining engine, infrastructure for expert data curation, and advanced visualization dashboards, including mindmaps, knowledge graphs, and 3-dimensional visualizations.

Visit our prototype dashboard to learn more:
https://www.deep-pharma.tech/dashboard

Strategic Consulting and Investment Advisory

Deep Pharma Intelligence offers a comprehensive range of consulting services, including comprehensive support for growth and investment decision making in the bio-pharmaceutical industry and related areas. It includes a wide range of services from market and competitor research, technology scouting and due diligence, to investment landscape profiling and comprehensive analytics support for investment decision-making.

Investment Digest "Artificial Intelligence for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview 2020"

The 60-page report offers the bird's eye view of the investment activity in the area of AI application for drug design, clinical research, and other biotech areas of high growth potential. It is an investor-oriented distillate of our landmark 130-page analytical report, covering **1000+** pharmaceutical entities, including **240+ startups, 600+ investors, 90+ corporations and 35 R&D centers**.

The Investment Digest is supported by our Big Data analytics Dashboard and IT-platform, offering advanced market intelligence, interactive mindmaps, benchmarking for companies, investors and technologies, competitive and SWOT analysis and more.

Some of the key takeaways from this digest include:

- **The segment of pharmaceutical AI continues consolidation;**
- **Pharmaceutical AI sector is "heating up" for investments;**
- **Big pharma and contract research organizations increasingly compete for AI partnerships;**
- **The sector of pharmaceutical AI is maturing for a likely wave of IPOs and M&As in 2021-2022;**
- **COVID-19 pandemics appears to be a positive catalyst for the acceleration of the AI adoption.**

● Number of corporations
● Number of AI companies
● Number of investors

Industry Growth

AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape / 2020

Preclinical Development

Clinical Development

AI Companies - 240
Investors - 600
Corporations - 90

End-to-end Drug Development

Drug Repurposing

AI Companies
Investors
Corporations

Pharma

Tech

CRO

Early And Preclinical Drug Development

Early drug development

DEEP PHARMA INTELLIGENCE

Pharma AI Deals Structure 2020

AI Companies				Pharma Corporations	Pharma Corporations	AI Companies		
Exscientia	Atomwise	turbine	CYCLICA	Bayer		SYSTEMS ONCOLOGY	RECURSION	SCHRÖDINGER
saama		XtalPi	Biovista	Pfizer		Atomwise	CytoReason	Insilico Medicine 英科智能
BERG	Alibaba Group	Tencent 腾讯		AstraZeneca		Benevolent		ProteinQure
FOUNDATION MEDICINE	RECURSION	Insilico Medicine 英科智能	WAVE	Takeda	gsk	Exscientia	CloudPharmaceuticals	Insilico Medicine 英科智能
BioSymetrics	RESONANT	DATAVANT		Janssen	Boehringer Ingelheim	Insilico Medicine 英科智能	BERG	NANNA
ReverieLabs	Genialis	Exscientia		Roche	SANOFI	Researchably	Exscientia	BERG
Atomwise	IKTOS	CYCLICA		MERCK	AMGEN	GNS HEALTHCARE	GeneTech	
sirenas		Concerto HealthAI		Bristol-Myers Squibb	abbvie	WuXi AppTec	Atomwise	
	e-therapeutics			novo nordisk	NOVARTIS	Benevolent	Biovista	
turbine				Johnson & Johnson	Celgene	Exscientia		
				evotec	astellas	Biovista		
CYCLICA				AUM BIOSCIENCES	VIVA	SCHRÖDINGER		
Genialis				OncXerna	ImmunoPrecise	EVQLV		
CYCLICA				YUHAN	almirall	IKTOS		
Atomwise				HANSOH PHARMA	GC	Atomwise		